Clinical Laboratory Improvement Advisory Committee (CLIAC), 9521 [2018-04475]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 44 / Tuesday, March 6, 2018 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Clinical Laboratory Improvement
Advisory Committee (CLIAC)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
for the Clinical Laboratory Improvement
Advisory Committee (CLIAC). This
meeting is open to the public, limited
only by the space available. The meeting
room accommodates approximately 100
people. The public is also welcome to
view the meeting by webcast. Check the
CLIAC website on the day of the
meeting for the webcast link https://
wwwn.cdc.gov/cliac/. Please see
information regarding attending the
meeting in the summary section below.
DATES: The meeting will be held on
April 10, 2018, 8:30 a.m. to 5:30 p.m.,
EDT and April 11, 2018, 8:30 a.m. to
1:00 p.m., EDT.
ADDRESSES: Food and Drug
Administration (FDA) White Oak
Campus, 10903 New Hampshire
Avenue, Building 31, Great Room,
Silver Spring, MD 20993.
FOR FURTHER INFORMATION CONTACT:
Nancy Anderson, MMSc, MT(ASCP),
Senior Advisor for Clinical Laboratories,
Division of Laboratory Systems, Center
for Surveillance, Epidemiology and
Laboratory Services, Office of Public
Health Scientific Services, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, Mailstop F–11,
Atlanta, Georgia 30329–4027 telephone
(404) 498–2741; NAnderson@cdc.gov.
SUPPLEMENTARY INFORMATION: All people
attending the CLIAC meeting in-person
are required to register for the meeting
online at least 5 business days in
advance for U.S. citizens and at least 10
business days in advance for
international registrants. Register at:
https://wwwn.cdc.gov/cliac/. Register by
scrolling down and clicking the
‘‘Register for this Meeting’’ button and
completing all forms according to the
instructions given. Please complete all
the required fields before submitting
your registration and submit no later
than April 2, 2018 for U.S. registrants
and March 26, 2018 for international
registrants.
It is the policy of CLIAC to accept
written public comments and provide a
brief period for oral public comments on
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
21:39 Mar 05, 2018
Jkt 244001
agenda items. Public comment periods
for each agenda item are scheduled
immediately prior to the Committee
discussion period for that item. In
general, each individual or group
requesting to make oral comments will
be limited to a total time of five minutes
(unless otherwise indicated). To assure
adequate time is scheduled for public
comments, speakers should notify the
contact person below at least 5 business
days prior to the meeting date. For
individuals or groups unable to attend
the meeting, CLIAC accepts written
comments until the date of the meeting
(unless otherwise stated). However, it is
requested that comments be submitted
at least 5 business days prior to the
meeting date so that the comments may
be made available to the Committee for
their consideration and public
distribution. Written comments, one
hard copy with original signature,
should be provided to the contact
person at the mailing or email address
below, and will be included in the
meeting’s Summary Report. The CLIAC
meeting materials will be made
available to the Committee and the
public in electronic format (PDF) on the
internet instead of by printed copy.
Check the CLIAC website on the day of
the meeting for materials: https://
wwwn.cdc.gov/cliac/.
Purpose: This Committee is charged
with providing scientific and technical
advice and guidance to the Secretary of
Health and Human Services (HHS); the
Assistant Secretary for Health; the
Director, Centers for Disease Control
and Prevention; the Commissioner,
Food and Drug Administration (FDA);
and the Administrator, Centers for
Medicare and Medicaid Services (CMS).
The advice and guidance pertain to
general issues related to improvement in
clinical laboratory quality and
laboratory medicine practice and
specific questions related to possible
revision of the Clinical Laboratory
Improvement Amendment (CLIA)
standards. Examples include providing
guidance on studies designed to
improve safety, effectiveness, efficiency,
timeliness, equity, and patientcenteredness of laboratory services;
revisions to the standards under which
clinical laboratories are regulated; the
impact of proposed revisions to the
standards on medical and laboratory
practice; and the modification of the
standards and provision of nonregulatory guidelines to accommodate
technological advances, such as new
test methods, the electronic
transmission of laboratory information,
and mechanisms to improve the
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
9521
integration of public health and clinical
laboratory practices.
Matters to be Considered: The agenda
will include agency updates from CDC,
CMS, and FDA. Presentations and
discussions will focus on the clinical
laboratory workforce; implementation of
next generation sequencing in clinical
laboratories; laboratory interoperability;
and using clinical laboratory data to
improve quality and laboratory
medicine practices. Agenda items are
subject to change as priorities dictate.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2018–04475 Filed 3–5–18; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Board on Radiation and
Worker Health (ABRWH or the
Advisory Board), National Institute for
Occupational Safety and Health
(NIOSH)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
of the Advisory Board on Radiation and
Worker Health (ABRWH). This meeting
is open to the public, limited only by
the space available. The meeting space
accommodates approximately 150
people. The public is welcome to
submit written comments in advance of
the meeting, to the contact person
below. Written comments received in
advance of the meeting will be included
in the official record of the meeting. The
public is also welcome to listen to the
meeting by joining the teleconference at
the USA toll-free, dial-in number at 1–
866–659–0537; the pass code is
9933701. The conference line has 150
ports for callers. The Web conference by
which the public can view presentations
SUMMARY:
E:\FR\FM\06MRN1.SGM
06MRN1
]]>Agencies
[Federal Register Volume 83, Number 44 (Tuesday, March 6, 2018)]
[Notices]
[Page 9521]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-04475]
[[Page 9521]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Laboratory Improvement Advisory Committee (CLIAC)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC
announces the following meeting for the Clinical Laboratory Improvement
Advisory Committee (CLIAC). This meeting is open to the public, limited
only by the space available. The meeting room accommodates
approximately 100 people. The public is also welcome to view the
meeting by webcast. Check the CLIAC website on the day of the meeting
for the webcast link https://wwwn.cdc.gov/cliac/. Please see
information regarding attending the meeting in the summary section
below.
DATES: The meeting will be held on April 10, 2018, 8:30 a.m. to 5:30
p.m., EDT and April 11, 2018, 8:30 a.m. to 1:00 p.m., EDT.
ADDRESSES: Food and Drug Administration (FDA) White Oak Campus, 10903
New Hampshire Avenue, Building 31, Great Room, Silver Spring, MD 20993.
FOR FURTHER INFORMATION CONTACT: Nancy Anderson, MMSc, MT(ASCP), Senior
Advisor for Clinical Laboratories, Division of Laboratory Systems,
Center for Surveillance, Epidemiology and Laboratory Services, Office
of Public Health Scientific Services, Centers for Disease Control and
Prevention, 1600 Clifton Road NE, Mailstop F-11, Atlanta, Georgia
30329-4027 telephone (404) 498-2741; [email protected].
SUPPLEMENTARY INFORMATION: All people attending the CLIAC meeting in-
person are required to register for the meeting online at least 5
business days in advance for U.S. citizens and at least 10 business
days in advance for international registrants. Register at: https://wwwn.cdc.gov/cliac/. Register by scrolling down and clicking the
``Register for this Meeting'' button and completing all forms according
to the instructions given. Please complete all the required fields
before submitting your registration and submit no later than April 2,
2018 for U.S. registrants and March 26, 2018 for international
registrants.
It is the policy of CLIAC to accept written public comments and
provide a brief period for oral public comments on agenda items. Public
comment periods for each agenda item are scheduled immediately prior to
the Committee discussion period for that item. In general, each
individual or group requesting to make oral comments will be limited to
a total time of five minutes (unless otherwise indicated). To assure
adequate time is scheduled for public comments, speakers should notify
the contact person below at least 5 business days prior to the meeting
date. For individuals or groups unable to attend the meeting, CLIAC
accepts written comments until the date of the meeting (unless
otherwise stated). However, it is requested that comments be submitted
at least 5 business days prior to the meeting date so that the comments
may be made available to the Committee for their consideration and
public distribution. Written comments, one hard copy with original
signature, should be provided to the contact person at the mailing or
email address below, and will be included in the meeting's Summary
Report. The CLIAC meeting materials will be made available to the
Committee and the public in electronic format (PDF) on the internet
instead of by printed copy. Check the CLIAC website on the day of the
meeting for materials: https://wwwn.cdc.gov/cliac/.
Purpose: This Committee is charged with providing scientific and
technical advice and guidance to the Secretary of Health and Human
Services (HHS); the Assistant Secretary for Health; the Director,
Centers for Disease Control and Prevention; the Commissioner, Food and
Drug Administration (FDA); and the Administrator, Centers for Medicare
and Medicaid Services (CMS). The advice and guidance pertain to general
issues related to improvement in clinical laboratory quality and
laboratory medicine practice and specific questions related to possible
revision of the Clinical Laboratory Improvement Amendment (CLIA)
standards. Examples include providing guidance on studies designed to
improve safety, effectiveness, efficiency, timeliness, equity, and
patient-centeredness of laboratory services; revisions to the standards
under which clinical laboratories are regulated; the impact of proposed
revisions to the standards on medical and laboratory practice; and the
modification of the standards and provision of non-regulatory
guidelines to accommodate technological advances, such as new test
methods, the electronic transmission of laboratory information, and
mechanisms to improve the integration of public health and clinical
laboratory practices.
Matters to be Considered: The agenda will include agency updates
from CDC, CMS, and FDA. Presentations and discussions will focus on the
clinical laboratory workforce; implementation of next generation
sequencing in clinical laboratories; laboratory interoperability; and
using clinical laboratory data to improve quality and laboratory
medicine practices. Agenda items are subject to change as priorities
dictate.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2018-04475 Filed 3-5-18; 8:45 am]
BILLING CODE 4163-19-P
